Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Insights into the molecular events that enable the immune system to control itself, particularly in relation to how T cells with regulatory or suppressor activity (Treg) develop and function, hold the key to developing new approaches for manipulating or controlling the aggressive unwanted immune responses in vivo, thereby preventing rejection. This information should facilitate the development of more-selective therapies that target only destructive immune responses without adversely affecting the beneficial, protective functions of the immune system. The induction of immunological unresponsiveness to defined sets of alloantigens remains a major unmet need in clinical transplantation. Novel immunotherapeutic agents should enable the development of effective immunosuppressive regimens that have reduced toxicity and lead to a regulated response after transplantation. © 2012 Blackwell Publishing Ltd.

Original publication




Journal article

Publication Date



62 - 78